[ANALYSIS OF THE ASSOCIATION BETWEEN IMMUNE-RELATED ADVERSE EVENTS AND THE EFFICACY OF PEMBROLIZUMAB IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA].

Hashizume, Akihito; Yamashita, Ryo; Shinsaka, Hideo; Nakamura, Masafumi; Matsuzaki, Masato; Niwakawa, Masashi

Hashizume, Akihito; Yamashita, Ryo; Shinsaka, Hideo; Nakamura, Masafumi; Matsuzaki, Masato; Niwakawa, Masashi.

Afiliación

Hashizume A; Division of Urology, Shizuoka Cancer Center.
Yamashita R; Division of Urology, Shizuoka Cancer Center.
Shinsaka H; Division of Urology, Shizuoka Cancer Center.
Nakamura M; Division of Urology, Shizuoka Cancer Center.
Matsuzaki M; Division of Urology, Shizuoka Cancer Center.
Niwakawa M; Division of Urology, Shizuoka Cancer Center.

Nihon Hinyokika Gakkai Zasshi ; 112(4): 179-184, 2021.

Article en Ja | MEDLINE | ID: mdl-36261347

Palabras clave

immune-related adverse events; urothelial carcinoma

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: Ja Revista: Nihon Hinyokika Gakkai Zasshi Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google